Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
By F. Hirsch, M. Varella-Garcia, P. Bunn, W. Franklin, R. Dziadziuszko, N. Thatcher, A. Chang, P. Parikh, J. R. Pereira, T. Ciuleanu and 9 more. Journal of Clinical Oncology, 2006
732 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/fc4132bd363a2977f79bbeef85ef6aa2925d050e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, background): “Of five studies that reported on survival by EGFR IHC results, four reported a significant survival benefit when the tumors stained positive.(128,129,141,150) Six studies reported EGFR gene copy number status as assessed by FISH, four of which showed a survival benefit for people with FISH-positive/”
- Targeting the EGFR signaling pathway in cancer therapy (2012, background): “Recent studies evaluating EGFR TKIs in patients with these activating EGFR gene mutations demonstrated a consistent improvement in progression-free survival, but none of these trials have demonstrated an improvement in overall survival [126-128].”